Marinova's clinical trial shows a marine algae extract alleviates benign prostate hyperplasia symptoms, opening a potential new nutraceutical avenue
Executive summary: Marinova announced that a randomized, double‑blind, placebo‑controlled clinical trial found its proprietary marine algae extract significantly improved symptoms of benign prostate hyperplasia. The result offers a possible plant‑based alternative to existing drug or supplement therapies for BPH, a condition affecting over condition affecting over 50 % of men over 50.
Who is involved: Marinova (Australian biotech), clinical trial investigators, study participants, and regulatory bodies overseeing supplement claims.
Likely next: Marinova is expected to publish the full data, pursue regulatory submissions for health claims in major markets, and explore commercial partnerships for product development.
The trial conducted by Marinova demonstrates that a unique marine algae extract can reduce urinary symptoms associated with BPH, based on patient‑reported outcomes. While the findings are promising, they stem from a single study and require independent replication and regulatory review before market entry. If substantiated, the extract could diversify the prostate health supplement market and provide a non‑pharmaceutical option for millions of men.
Timeline
- — Se ha demostrado que el extracto de algas marinas alivia los síntomas de la próstata (PR Newswire)
- — Un extrait d'algues s'avère efficace pour soulager les symptômes de la prostate (PR Newswire)
- — Algenextrakt lindert nachweislich Prostatabeschwerden (PR Newswire)
Analysis — what this means
Sectors affected
- nutraceutical supplements
- prostate health products
- marine algae ingredients
Regulatory implications
- Health claim substantiation required under FDA/EFSA regulations for prostate health benefits